yes as the FDA decision was made available on Saturday March 11....

yes as the FDA decision was made available on Saturday March 11. The market hasn’t woken up to this yet - waiting for Acadia to take the lead in the US overnight then I expect a siginificant uptick again tomorrow. Market didn’t know what to do. We are all waiting on the drug costing to plug into models - expected to be around $150000 p.a per patient reimbursed by insurers. May be more may be less. ASX has so few successful biotechs I genuinely think that most analysts just are lost on valuations for these. Botanix has suffered from this previously - dropping in value after a successful phase 2 study. The mind boggles.